Suchergebnisse
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant IMVT incurred first-quarter fiscal 2027 net loss of 75 cents per share, wider than the Zacks Consensus Estimate of a loss of 66 cents. The company had reported a loss of 71 cents per
